+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are studying treatments for adults with locally advanced unresectable or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors overexpress HER2 and have PD-L1 TPS less than 50%. This trial compares the combination of trastuzumab deruxtecan T-DXd with pembrolizumab against platinum-based chemotherapy combined with pembrolizumab. Participants have not received prior therapy for their advanced or metastatic NSCLC and lack known actionable genomic alterations with available targeted treatments. The study involves two treatment groups. One group receives T-DXd at 5.4 mgkg intravenously every three weeks alongside pembrolizumab at 200 mg IV every three weeks. The other group receives pemetrexed at 500 mgm IV every three weeks plus a platinum chemotherapy agent cisplatin or carboplatin combined with pembrolizumab at 200 mg IV every three weeks. Treatment continues as per protocol for first-line therapy in this population. Participants will be monitored regularly for disease progression and survival outcomes, with progression-free survival assessed by independent central review up to approximately 54 months and overall survival up to about 85 months. Tumor tissue samples will be assessed for HER2 and PD-L1 expression. Safety and treatment effects will be evaluated throughout the study, which may last several years until study completion in 2032.

Age: 18Years +All GendersPhase 3
246 locations